GSK Halts Alector's Phase 2 Nivisnebart Trial on Futility; Q1 Revenue Plummets 71%
summarizeSummary
Alector, Inc. reported its first-quarter 2026 results, revealing a significant 71.5% year-over-year decline in revenue to $1.05 million, alongside a net loss of $22.93 million. The most critical update, however, is the discontinuation of the Phase 2 nivisnebart (PROGRESS-AD) study by partner GSK following an interim futility analysis. This clinical setback is a major blow to Alector's pipeline, especially given the company's prior history of clinical trial failures and extensive workforce reductions highlighted in its 2025 10-K. While the net loss narrowed year-over-year, this improvement is likely attributable to reduced R&D spending rather than operational strength, as the company shifts focus to its preclinical ABC platform with an IND target of Q1 2027. The substantial decline in collaboration revenue further underscores the challenges in its existing partnerships. Investors will closely monitor the progress of Alector's preclinical programs and its ability to sustain operations with its $206.5 million liquidity through 2027.
At the time of this announcement, ALEC was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.9M. The 52-week trading range was $0.97 to $3.40. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.